» Articles » PMID: 37001838

Nano Based-oncolytic Viruses for Cancer Therapy

Overview
Specialty Hematology
Date 2023 Mar 31
PMID 37001838
Authors
Affiliations
Soon will be listed here.
Abstract

Oncolytic viruses (OV) are an attractive prospect due to their dual attack mechanism of direct cell lysis and potentiation of an antitumor immune response. Various oncolytic viral vectors are used in oncotherapy clinical trials, and one of their main problems is elimination by the reticuloendothelial system during systemic delivery. Nanoparticles (NPs) have received much attention in clinical trials due to their unique appearance characteristics, but they have created challenges due to the non-specificity of drug delivery to the target tissue and its elimination in blood circulation. In this regard, to increase the efficiency of nanoparticles in drug delivery, various chemical modifications can be applied to the surface of nanoparticles. To improve the performance of these two treatment options, the complex strategy of OVs encapsulated with nanoparticles can be used, which has brought successful clinical results in the treatment of various cancers. Here we will review each of the treatment methods and their functional mechanism.

Citing Articles

Exploring ferroptosis and miRNAs: implications for cancer modulation and therapy.

Ajam-Hosseini M, Babashah S Mol Cell Biochem. 2025; .

PMID: 39869280 DOI: 10.1007/s11010-024-05169-9.


A Novel Oncolytic Virus Formulation Based on Mesenchymal Stem Cell-Derived Vesicles for Tumor Therapy.

Zeng F, Huang Y, Xu B, Yao L, Zhang Y, Gao Z J Cancer. 2025; 16(3):700-707.

PMID: 39781350 PMC: 11705066. DOI: 10.7150/jca.104066.


Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses.

Thoidingjam S, Bhatnagar A, Sriramulu S, Siddiqui F, Nyati S Int J Mol Sci. 2024; 25(18).

PMID: 39337402 PMC: 11432658. DOI: 10.3390/ijms25189912.


miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.

Toropko M, Chuvpilo S, Karabelsky A Pharmaceutics. 2024; 16(8).

PMID: 39204331 PMC: 11360794. DOI: 10.3390/pharmaceutics16080986.


Gram-negative bacterial sRNAs encapsulated in OMVs: an emerging class of therapeutic targets in diseases.

Ajam-Hosseini M, Akhoondi F, Parvini F, Fahimi H Front Cell Infect Microbiol. 2024; 13:1305510.

PMID: 38983695 PMC: 11232669. DOI: 10.3389/fcimb.2023.1305510.